Cargando…

The Debatable Benefit of Gross-Total Resection of Brain Metastases in a Comprehensive Treatment Setting

SIMPLE SUMMARY: In this monocentric retrospective analysis, the extent of resection of singular/solitary brain metastases has no impact on local recurrence and overall survival rates in patients receiving multidisciplinary adjuvant treatment. Since systemic disease progression is the leading cause o...

Descripción completa

Detalles Bibliográficos
Autores principales: Jünger, Stephanie T., Pennig, Lenhard, Schödel, Petra, Goldbrunner, Roland, Friker, Lea, Kocher, Martin, Proescholdt, Martin, Grau, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004079/
https://www.ncbi.nlm.nih.gov/pubmed/33801110
http://dx.doi.org/10.3390/cancers13061435
_version_ 1783671840558809088
author Jünger, Stephanie T.
Pennig, Lenhard
Schödel, Petra
Goldbrunner, Roland
Friker, Lea
Kocher, Martin
Proescholdt, Martin
Grau, Stefan
author_facet Jünger, Stephanie T.
Pennig, Lenhard
Schödel, Petra
Goldbrunner, Roland
Friker, Lea
Kocher, Martin
Proescholdt, Martin
Grau, Stefan
author_sort Jünger, Stephanie T.
collection PubMed
description SIMPLE SUMMARY: In this monocentric retrospective analysis, the extent of resection of singular/solitary brain metastases has no impact on local recurrence and overall survival rates in patients receiving multidisciplinary adjuvant treatment. Since systemic disease progression is the leading cause of death, and an uncontrolled systemic disease status, along with adjuvant treatment, present independent predictors of overall survival, a comprehensive, multidisciplinary treatment concept is essential for patients with brain metastases. ABSTRACT: Background and Purpose: The value of gross-total surgical resection remains debatable in patients with brain metastases (BMs) as most patients succumb to systemic disease progression. In this study, we evaluated the impact of the extent of resection of singular/solitary BM on in-brain recurrence (iBR), focusing on local recurrence (LR) and overall survival (OS) in an interdisciplinary adjuvant treatment setting. Patients and Methods: In this monocentric retrospective analysis, we included patients receiving surgery of one BM and subsequent adjuvant treatment. A radiologist and a neurosurgeon determined in consensus the extent of resection based on magnetic resonance imaging. The OS was calculated using Kaplan–Meier estimates; prognostic factors for LR and OS were analysed by Log rank test and Cox proportional hazards. Results: We analyzed 197 patients. Gross-total resection was achieved in 123 (62.4%) patients. All patients were treated with adjuvant radiotherapy, and 130 (66.0%) received systemic treatment. Ninety-six (48.7%) patients showed iBR with an LR rate of 23.4%. LR was not significantly influenced by the extent of resection (p = 0.139) or any other parameter. The median OS after surgery was 18 (95%CI 12.5–23.5) months. In univariate analysis, the extent of resection did not influence OS (p = 0.6759), as opposed to adjuvant systemic treatment (p < 0.0001) and controlled systemic disease (p = 0.039). Systemic treatment and controlled disease status remained independent factors for OS (p < 0.0001 and p = 0.009, respectively). Conclusions: In this study, the extent of resection of BMs neither influenced the LR nor the OS of patients receiving interdisciplinary adjuvant treatment.
format Online
Article
Text
id pubmed-8004079
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-80040792021-03-28 The Debatable Benefit of Gross-Total Resection of Brain Metastases in a Comprehensive Treatment Setting Jünger, Stephanie T. Pennig, Lenhard Schödel, Petra Goldbrunner, Roland Friker, Lea Kocher, Martin Proescholdt, Martin Grau, Stefan Cancers (Basel) Article SIMPLE SUMMARY: In this monocentric retrospective analysis, the extent of resection of singular/solitary brain metastases has no impact on local recurrence and overall survival rates in patients receiving multidisciplinary adjuvant treatment. Since systemic disease progression is the leading cause of death, and an uncontrolled systemic disease status, along with adjuvant treatment, present independent predictors of overall survival, a comprehensive, multidisciplinary treatment concept is essential for patients with brain metastases. ABSTRACT: Background and Purpose: The value of gross-total surgical resection remains debatable in patients with brain metastases (BMs) as most patients succumb to systemic disease progression. In this study, we evaluated the impact of the extent of resection of singular/solitary BM on in-brain recurrence (iBR), focusing on local recurrence (LR) and overall survival (OS) in an interdisciplinary adjuvant treatment setting. Patients and Methods: In this monocentric retrospective analysis, we included patients receiving surgery of one BM and subsequent adjuvant treatment. A radiologist and a neurosurgeon determined in consensus the extent of resection based on magnetic resonance imaging. The OS was calculated using Kaplan–Meier estimates; prognostic factors for LR and OS were analysed by Log rank test and Cox proportional hazards. Results: We analyzed 197 patients. Gross-total resection was achieved in 123 (62.4%) patients. All patients were treated with adjuvant radiotherapy, and 130 (66.0%) received systemic treatment. Ninety-six (48.7%) patients showed iBR with an LR rate of 23.4%. LR was not significantly influenced by the extent of resection (p = 0.139) or any other parameter. The median OS after surgery was 18 (95%CI 12.5–23.5) months. In univariate analysis, the extent of resection did not influence OS (p = 0.6759), as opposed to adjuvant systemic treatment (p < 0.0001) and controlled systemic disease (p = 0.039). Systemic treatment and controlled disease status remained independent factors for OS (p < 0.0001 and p = 0.009, respectively). Conclusions: In this study, the extent of resection of BMs neither influenced the LR nor the OS of patients receiving interdisciplinary adjuvant treatment. MDPI 2021-03-21 /pmc/articles/PMC8004079/ /pubmed/33801110 http://dx.doi.org/10.3390/cancers13061435 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Jünger, Stephanie T.
Pennig, Lenhard
Schödel, Petra
Goldbrunner, Roland
Friker, Lea
Kocher, Martin
Proescholdt, Martin
Grau, Stefan
The Debatable Benefit of Gross-Total Resection of Brain Metastases in a Comprehensive Treatment Setting
title The Debatable Benefit of Gross-Total Resection of Brain Metastases in a Comprehensive Treatment Setting
title_full The Debatable Benefit of Gross-Total Resection of Brain Metastases in a Comprehensive Treatment Setting
title_fullStr The Debatable Benefit of Gross-Total Resection of Brain Metastases in a Comprehensive Treatment Setting
title_full_unstemmed The Debatable Benefit of Gross-Total Resection of Brain Metastases in a Comprehensive Treatment Setting
title_short The Debatable Benefit of Gross-Total Resection of Brain Metastases in a Comprehensive Treatment Setting
title_sort debatable benefit of gross-total resection of brain metastases in a comprehensive treatment setting
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8004079/
https://www.ncbi.nlm.nih.gov/pubmed/33801110
http://dx.doi.org/10.3390/cancers13061435
work_keys_str_mv AT jungerstephaniet thedebatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting
AT penniglenhard thedebatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting
AT schodelpetra thedebatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting
AT goldbrunnerroland thedebatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting
AT frikerlea thedebatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting
AT kochermartin thedebatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting
AT proescholdtmartin thedebatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting
AT graustefan thedebatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting
AT jungerstephaniet debatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting
AT penniglenhard debatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting
AT schodelpetra debatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting
AT goldbrunnerroland debatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting
AT frikerlea debatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting
AT kochermartin debatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting
AT proescholdtmartin debatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting
AT graustefan debatablebenefitofgrosstotalresectionofbrainmetastasesinacomprehensivetreatmentsetting